|
|
World Heart Corporation - Comparative Business Analysis Snapshot
Business Description
World Heart Corporation. The Group's principal activity is to develop artificial heart technologies. The Group is focused on two technologies: Novacor LVAS and the HeartSaver Ventricular Assist Device (HeartSaver). Novacor technology is currently in commercial production and the HeartSaver technology is currently under development. This technology is being developed from licensed artificial heart and related technologies developed by the Cardiovascular Devices Division (CVD) of the Ottawa Heart Institute Research Corporation. The Group operates in Canada and the United States.
Competitor Analysis
This analysis compares World Heart Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
